Articles dans des revues avec comité de lecture (30)
  1. 1. Kassas, M., Devriendt, L., Manley, M., Guiot, T., Marin, C., Danieli, R., Taraji-Schiltz, L., Kristanto, P., Karfis, I., Woff, E., Flamen, P., & Artigas Guix, C. (2025). [177Lu]Lu-PSMA SPECT/CT for early response assessment using quantitative RECIP 1.0. European journal of nuclear medicine and molecular imaging. doi:10.1007/s00259-025-07613-4
  2. 2. Paquier, Z., Dhont, J., Guiot, T., Levillain, H., Critchi, G., Saúde Conde, R., Sclafani, F., Flamen, P., Reynaert, N., Woff, E., & Hendlisz, A. (2025). Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer. JCO Clinical Cancer Informatics, 9, e2400207. doi:10.1200/CCI-24-00207
  3. 3. Paquier, Z., Dhont, J., Guiot, T., Levillain, H., Critchi, G., Saúde-Conde, R., Sclafani, F., Flamen, P., Reynaert, N., Woff, E., & Hendlisz, A. (2025). Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer. JCO Clinical Cancer Informatics, 9, e2400207. doi:10.1200/CCI-24-00207
  4. 4. Rediti, M., Fimereli, D., Mileva, M., Wimana, Z., Venet, D., Flamen, P., Guiot, T., de Vries, E. E., Schröder, C. P., Menke-van der Houven van Oordt, W. C., Maetens, M. M., Majjaj, S., Larsimont, D., Rothé, F., Sotiriou, C., & Gebhart, G. (2025). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical cancer research, 31(1), 110-121. doi:10.1158/1078-0432.CCR-24-1007
  5. 5. Mileva, M., de Vries, E. E., Guiot, T., Wimana, Z., Deleu, A.-L., Schröder, C. P., Lefebvre, Y., Paesmans, M., Stroobants, S., Huizing, M. T., Aftimos, P., Tol, J., Van Der Graaf, W. T. A., Oyen, W. J. G., Vugts, D., Menke-van der Houven van Oordt, W. C., Brouwers, A. A., Piccart-Gebhart, M., Flamen, P., & Gebhart, G. (2024). Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ breast cancer, 10(1), 4. doi:10.1038/s41523-023-00610-6
  6. 6. Mokhtari, A., Casale, R., Salahuddin, Z., Paquier, Z., Guiot, T., Woodruff, H. H., Lambin, P., Van Laethem, J.-L., Hendlisz, A., & Bali, M. A. (2024). Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Diagnostics, 14(7), 712. doi:10.3390/diagnostics14070712
  7. 7. Llombart-Cussac, A., Prat, A., Pérez-García, J. M., Mateos, J., Pascual, T., Escrivá-de-Romani, S., Stradella, A., Ruiz Borrego, M., de las Heras, B., Keyaerts, M., Galvan, P., Brasó-Maristany, F., García-Mosquera, J. J., Guiot, T., Gion, M., Sampayo-Cordero, M., Di Cosimo, S., Pérez-Escuredo, J., de Frutos, M. A., Cortes, J., & Gebhart, G. (2024). Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European journal of nuclear medicine and molecular imaging. doi:10.1007/s00259-024-06683-0
  8. 8. Shagera, Q. A., Karfis, I., Sideris, S., Guiot, T., Woff, E., Chanzá, N. M., Roumeguere, T., Gil, T., Flamen, P., & Artigas, C. (2023). Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel. Clinical nuclear medicine, 48(9), 775-780. doi:10.1097/RLU.0000000000004763
  9. 9. Paquier, Z., Chao, S.-L., Bregni, G., Sanchez Corujo, A., Guiot, T., Dhont, J., Gulyban, A., Levillain, H., Sclafani, F., Reynaert, N., & Bali, M. A. (2022). Pre-trial quality assurance of diffusion-weighted MRI for radiomic analysis and the role of harmonisation. Physica medica, 103, 138-146. doi:10.1016/j.ejmp.2022.10.009
  10. 10. Paquier, Z., Chao, S.-L., Acquisto, A., Fenton, C., Guiot, T., Dhont, J., Levillain, H., Gulyban, A., Bali, M. A., & Reynaert, N. (2022). Radiomics software comparison using digital phantom and patient data: IBSI-compliance does not guarantee concordance of feature values. Biomedical Physics & Engineering Express, 8(6), 065008. doi:10.1088/2057-1976/ac8e6f
  11. 11. Woff, E., Salvatore, L., Marmorino, F., Genovesi, D., Critchi, G., Guiot, T., Ameye, L., Sclafani, F., Hendlisz, A., & Flamen, P. (2022). Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer. The Journal of nuclear medicine, 63(4), 549-555. doi:10.2967/jnumed.120.245357
  12. 12. Gombos, A., Venet, D., Ameye, L., Vuylsteke, P., Neven, P., Richard, V., Duhoux, F. F., Laes, J.-F., Rothé, F., Sotiriou, C., Paesmans, M., Awada, A., Guiot, T., Flamen, P., Piccart-Gebhart, M., Ignatiadis, M., & Gebhart, G. (2021). FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. NPJ breast cancer, 7(1), 125. doi:10.1038/s41523-021-00331-8
    13. << Précédent 1 2 3 Suivant >>